Business Wire

SHIPPEO

22.5.2023 17:46:25 CEST | Business Wire | Press release

Share
Shippeo Recognized in the 2023 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms

Shippeo, a global leader in real-time multimodal transportation visibility, today announced it has been recognized in the Gartner® Magic Quadrant™ for Real-time Transportation Visibility Platforms.

“I am pleased to see many of Shippeo’s recognitions over the past 12 months reflected, we believe, in our positioning in this year’s Magic Quadrant,” says Shippeo co-founder and COO, Lucien Besse.

Shippeo has a 95% willingness to recommend rating on Gartner Peer Insights™, receiving the overall rating of 4.8/5*. “These are highly important metrics for us, and reassure us that we are providing our customers with the best value, and delivering what we promise,” says Besse, adding “we believe this high customer satisfaction was helped by the fact we are the only provider to offer a triple SLA, which contractually guarantees rapid carrier onboarding, high tracking rates, and high ETA accuracy, as well as the tremendous progress we have made across all aspects of our business over the last 12 months.”

The company recently raised a record $50m in fundraising, with all existing investors taking part. “This fundraising round is the largest ever for a supply chain visibility software in Europe,” explains Besse. “It will help us bolster our sound financial position for many years to come, and accelerate our ongoing North American and APAC expansion, while giving customers and partners confidence in the longevity potential of our partnerships with the strong path to profitability we’ve laid out as a company.”

Existing investors taking part included Battery Ventures, Partech, NGP Capital, ETF Partners, Bpifrance Digital Venture and SAP.io. Notable new strategic investors include Hong Kong-based LFX Venture Partners and Japan-based Yamaha Motor Ventures, whose investment is helping to ramp up operations across Asia-Pacific, as well as Orlen VC, based in Poland, and Shift4good, a global VC fund dedicated to impact investing in smart mobility and circular economy businesses.

An expert in sustainability, Shift4good strictly invests in companies with the potential to move the needle on climate change. Beyond a strong belief in the company’s business potential, Shift4Good’s decision to invest was driven by the potential of Shippeo’s new Carbon Visibility solution to have a positive impact across the transportation and logistics sector. The emissions calculator, now generally available to all customers, combines Shippeo’s advanced visibility data capabilities with cutting edge data modeling from industry expert Searoutes, to provide extremely accurate transport and distribution GHG (CO2e) emissions reporting. The tool offers users GLEC-accredited CO2 equivalent emissions calculations, without the need to manually consolidate data supplied by carriers.

Continued expansion into North America and APAC was boosted by a new global partnership with e2open, offering Shippeo’s native real-time in-transit visibility within their comprehensive global supply chain management platform.

The company also recently welcomed some of the most iconic brands in the world, including Amazon, Barilla (US), Epson, Geodis, Jacob Douwe Egberts (JDE), Jaguar Land Rover, Lassonde, L'Oréal, Moët Hennessy (LVMH), SABIC International (the second largest public company in the Middle East) and Siemens Energy.

Over the last year, Shippeo’s team grew to more than 230 Shippians, including senior executive and SaaS veteran Philippe Vanhove as new Chief Revenue Officer, who brings 25 years of experience in scaling fast-growing, international SaaS organizations, having managed multinational sales operations, marketing, lead generation, human resources, and finance.

In April, the company launched a new biannual platform release cycle, delivering its latest Spring platform release. New and enhanced features across all transport modes introduced to users improve the platform experience and enhance visibility data quality. Highlights include a new Shippeo berth ETA as part of their Ocean Visibility offering, which is significantly more accurate and reliable than the ones received from ocean carriers, as well as new vessel AIS-based milestone detection for more accurate milestones at ports during loading, unloading and transshipment. A swathe of usability enhancements throughout the multimodal visibility platform include new container delay filters, carrier TMS tag synchronization, and configurable notifications to help users manage shipments more efficiently, by exception.

2022 also saw the launch of Shippeo’s Carrier Recognition Program, celebrating over 400 of the world’s most exceptional carriers, who provide the best service to shippers with consistently high levels of shipment tracking. The company also held their inaugural Visibility Star Awards last November, which recognize the efforts our carrier community has made to provide great service to their clients, and celebrate their exceptional commitment to real-time visibility.

More information:

*Disclaimer:
* Gartner Disclaimer: based on 214 reviews as of May 18 2023 in the Real-Time Transportation Visibility Platforms market.

Gartner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2023” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 16 May 2023.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains. This is made possible with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Siemens Energy, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com
LinkedIn, Facebook, Twitter

About Shift4Good
Shift4Good is a venture capital fund manager dedicated to impact investing in smart mobility & circular economy start-ups. With teams based in both Paris and Singapore, Shift4Good mostly focus on European and Southeast Asian opportunities. Shift4Good can deploy between €0.5m and €20m per company and mostly invest in Series A and Series B rounds and can allocate 10% of their funds to pre-Series A rounds. More information: https://www.shift4good.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005162/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye